BiotechTube

Mavacamten + Placebo

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obstructive Hypertrophic Cardiomyopathy

Conditions

Obstructive Hypertrophic Cardiomyopathy

Trial Timeline

Jan 4, 2022 → Jul 22, 2024

NCT ID
NCT05174416

About Mavacamten + Placebo

Mavacamten + Placebo is a phase 3 stage product being developed by LianBio for Obstructive Hypertrophic Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05174416. Target conditions include Obstructive Hypertrophic Cardiomyopathy.

What happened to similar drugs?

20 of 20 similar drugs in Obstructive Hypertrophic Cardiomyopathy were approved

Approved (20) Terminated (2) Active (0)
✅lysozyme 90 mg + PlaceboEisaiApproved
✅Eszopiclone + Placebo controlSumitomo PharmaApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Lunesta + Placebo controlSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05174416Phase 3Completed

Competing Products

20 competing products in Obstructive Hypertrophic Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Daridorexant + PlaceboIdorsiaPhase 1
23
CT-G20 + PlaceboCelltrionPhase 1
21
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mgEisaiPhase 1
29
lysozyme 90 mg + PlaceboEisaiApproved
43
Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mgEisaiPhase 1
29
Eloralintide + PlaceboEli LillyPhase 3
47
Tirzepatide + PlaceboEli LillyPhase 3
40
Arformoterol tartrate inhalation solution + Arformoterol 25 ųg BID + Formoterol 12 ųg BID + PlaceboSumitomo PharmaPhase 3
40
arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + arformoterol tartrate inhalation solution + Salmeterol + PlaceboSumitomo PharmaPhase 3
40
arformoterol + salmeterolSumitomo PharmaPre-clinical
26
Eszopiclone + PlaceboSumitomo PharmaPhase 2
35
Arformoterol + PlaceboSumitomo PharmaPhase 3
40
Eszopiclone + Placebo controlSumitomo PharmaApproved
43
Eszopiclone + PlaceboSumitomo PharmaPhase 1
29
Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
43
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
35
Lunesta + Placebo controlSumitomo PharmaApproved
43
Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
39
Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
43